Lipid composition for the delivery of therapeutic cargos

Abstract

A construct includes a core comprising an external surface and a plurality of pores, a cargo disposed in a pore of the plurality of pores, the cargo comprising a CRISPR Cas9 component or a nucleic acid sequence encoding a CRISPR Cas9 component; and a coating coupled to the core, wherein the coating comprises a cationic lipid, a pegylated lipid, a zwitterionic lipid, and a sterol. The coating may comprise a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%. A method of treatment is also provided.

1 . A construct comprising:
 a core comprising an external surface and a plurality of pores, wherein an average dimension of the plurality of pores is greater than about 2 nm;   a cargo disposed in a pore of the plurality of the pores, the cargo comprising one or more selected from the group consisting of: peptides, proteins, nucleic acids, mRNA, aptamers, antibodies, pharmaceuticals, antisense oligonucleotides, alpha/flavi virus inhibitors, coronavirus inhibitors, carbohydrates, dyes, and markers; and   a coating coupled to the core, wherein the coating comprises a cationic lipid, a pegylated lipid, a zwitterionic lipid, and a sterol;   wherein the coating comprises a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%; or   wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane, the zwitterionic lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, the sterol is cholesterol, and the PEGylated lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000].   
     
     
         2 . The construct of  claim 1 , wherein the coating comprises a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%. 
     
     
         3 . (canceled) 
     
     
         4 . The construct of  claim 1 , further comprising a pharmaceutically acceptable excipient. 
     
     
         5 . The construct of  claim 1 , wherein the core is a stellate mesoporous silica nanoparticle. 
     
     
         6 . The construct of  claim 1 , wherein the average diameter of the plurality of pores is of from about 3 nm to about 20 nm as determined by porosimetry with nitrogen adsorption-desorption analysis. 
     
     
         7 . The construct of  claim 6 , wherein the core has an average diameter of about 75 to about 400 nm. 
     
     
         8 . A method of treating a subject, the method comprising:
 administering to a subject in need thereof, an effective amount of a construct, the construct including:   a core comprising an external surface and a plurality of pores, wherein an average dimension of the plurality of pores is greater than about 2 nm;   a cargo disposed in a pore of the plurality of pores, the cargo comprising a CRISPR Cas9 component, or a nucleic acid sequence encoding a CRISPR Cas9 component; and   a coating coupled to the core, wherein the coating comprises a cationic lipid, a PEGylated lipid, a zwitterionic lipid, and a sterol.   
     
     
         9 . The method of  claim 8 , wherein the core is a stellate mesoporous silica nanoparticle. 
     
     
         10 . The method of  claim 8 , wherein the average diameter of the plurality of pores is of from about 3 nm to about 20 nm as determined by porosimetry with nitrogen adsorption-desorption analysis. 
     
     
         11 . The method of  claim 8 , wherein the core has an average diameter of about 75 to about 400 nm. 
     
     
         12 . The method of  claim 9 , wherein the mesoporous silica nanoparticle is monodisperse in particle diameter, wherein about 90% of the distribution lies within about 5% of the median diameter, as measured by dynamic light scattering. 
     
     
         13 . The method of  claim 8 , wherein the coating comprises about 10 to about 50 mol % of the cationic lipid and zwitterionic lipid, about 5 to about 45 mol. % of the sterol, and about 2 to 8 mol. % of the PEGylated lipid. 
     
     
         14 . The method of  claim 8 , wherein the coating comprises about 20 to about 40 mol % of the cationic lipid and zwitterionic lipid, about 10 to about 35 mol. % of the sterol, and about 2.5 to 6 mol. % of the PEGylated lipid. 
     
     
         15 . The method of  claim 8 , wherein the coating comprises a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%. 
     
     
         16 . The method of  claim 8 , wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane, the zwitterionic lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, the sterol is cholesterol, and the PEGylated lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000]. 
     
     
         17 . The method of  claim 8 , wherein the sterol is selected from the group consisting of: cholesterol, desmosterol, diplopterol, cholestanol, cholic acid, 12-deoxycholic acid, 7-deoxycholic acid, or a derivative thereof, and mixtures thereof and conjugated forms thereof. 
     
     
         18 . The method of  claim 8 , wherein the coating comprises a molar ratio of 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%; and
 wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane, the zwitterionic lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, the sterol is cholesterol, and the PEGylated lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000].   
     
     
         19 . The method of  claim 8 , wherein the cargo of the construct is configured to bind to a target sequence of the subject. 
     
     
         20 . The method of  claim 8 , wherein the cargo is a coronavirus inhibitor. 
     
     
         21 . The construct of  claim 1 , wherein the cargo is a coronavirus inhibitor.